A Clinical Study to Evaluate the Relative Bioavailability of MK-1403 Formulations Administered to Healthy Adult Participants
Merck Sharp & Dohme LLC
Summary
The purpose of this trial is to learn about a trial medicine called MK-1403. Researchers designed MK-1403 to treat a type of heart and blood vessel disease called atherosclerotic cardiovascular disease (ASCVD). Before giving a trial medicine to people with a health condition, researchers first do clinical trials in healthy people. This trial will help researchers learn about the safety of MK-1403 and if participants tolerate it. Tolerate means participants receive the trial medicine and they do not need to stop taking it due to health problems. The trial will also measure what happens to MK 1403 in a healthy person's body over time.
Eligibility
- Age range
- 18–55 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Is in good health * Has a body mass index (BMI) ≥ 18 and ≤ 32 kg/m\^2 Exclusion Criteria: * Has history of cancer (malignancy) * Has a history of significant multiple and/or severe allergies
Interventions
- DrugMK-1403 formulation (FM) 1 + additive
Oral tablet
- DrugMK-1403 FM2 + additive
Oral tablet
Location
- Qps-Mra, LlcMiami, Florida